Neuroproof

NeuroProof is a leading contract research organization (CRO) specializing in neuropharmacological drug discovery and functional neurotoxicity testing. The company leverages high-density microelectrode array (MEA) technology to record and analyze the electrical activity of primary neuronal networks and human iPSC-derived neurons. By employing sophisticated bioinformatics and machine learning algorithms, NeuroProof provides detailed phenotypic characterization of drug effects, enabling the identification of disease-specific signatures and potential therapeutic leads. Their services are critical for evaluating compounds targeting central nervous system disorders such as Alzheimer's, Parkinson's, and epilepsy. NeuroProof supports global pharmaceutical and biotechnology companies through all stages of preclinical development, from hit identification to safety profiling.